Who Paid My Doc
Robert Zemble
Allergy & Immunology Allentown, PA Medical Doctor
NPI 1124224027 CMS profile 142064
1605 N Cedar Crest Blvd Ste 605, Allentown, PA 18104
General payments
$13,967
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Robert Zemble of Allentown, PA is reported in the CMS Open Payments database as having received $13,967 across 457 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 84th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $830 | 9 | |
| 2024 | General | $3,529 | 5 | |
| 2023 | General | $2,630 | 99 | |
| 2022 | General | $2,018 | 87 | |
| 2021 | General | $2,055 | 103 | |
| 2020 | General | $1,394 | 76 | |
| 2019 | General | $1,511 | 78 |
Beside peers
- Robert Zemble
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Robert Zemble were reported at $830. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.
Show as a table
| Year | Robert Zemble | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,511 | $378 | $115–$1,178 | $163 |
| 2020 | $1,394 | $303 | $75–$1,581 | $114 |
| 2021 | $2,055 | $407 | $122–$1,475 | $132 |
| 2022 | $2,018 | $357 | $120–$1,340 | $149 |
| 2023 | $2,630 | $445 | $124–$1,536 | $160 |
| 2024 | $3,529 | $541 | $129–$1,763 | $164 |
| 2025 | $830 | $682 | $143–$2,317 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 27 drugsPart D claims
1,078
Drug cost
$445,292
Branded share of claims
42.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 38 | $139,507 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 55 | $63,077 | |
| Dupixent Syringe Dupilumab | Brand | 15 | $56,177 | |
| Xolair Omalizumab | Brand | 28 | $39,035 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 22 | $17,766 | |
| Dulera Mometasone/Formoterol | Brand | 32 | $16,932 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 33 | $16,438 | |
| Arnuity Ellipta Fluticasone Furoate | Brand | 25 | $14,699 | |
| Advair Hfa Fluticasone Propion/Salmeterol | Brand | 22 | $14,552 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 45 | $9,960 |
The 10 drugs with the highest cost, of 27 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 38 billing codesPaid by Medicare
$160,613
Medicare patients
221
Services billed
7,205
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 53% | |
| Diabetes | 31% | |
| Depression | 29% | |
| Ischemic heart disease | 22% | |
| Osteoporosis | 20% | |
| Chronic kidney disease | 17% | |
| COPD | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 20 | 20 | $1,627 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
457 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in Pennsylvania
Drew Weissman
Allergy & Immunology · Philadelphia, PA
Karin Flynn-Rodden
Allergy & Immunology · Philadelphia, PA
Joel Eisner
Allergy & Immunology · Phoenixville, PA
Ulyana Trytko
Allergy & Immunology · Allentown, PA
Jennifer Brennan-Phillip
Allergy & Immunology · Newtown, PA
Ali Ayyash
Allergy & Immunology · Pittsburgh, PA
Related records
Allergy & Immunology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.